A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.

摘要: Our laboratory has described a drug-responsive NADH oxidase activity of the external surface plasma membrane HeLa and other cancer cells, but not from normal that was shed into media conditioned by growth cells such as HeLa. The form exhibited same drug responsiveness membrane-associated form. In this study, sera tumor-bearing control rats, patients, volunteers, patients with diseases than were collected assayed for cancer-specific responsive to antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984). With rats LY181984 added at final concentration 1 μM either inhibited or stimulated activity. disorders cancer, without effect on sera. altered present both in freshly stored frozen. Inhibition half maximal about 30 nM LY181984. sulfonylurea-altered found nearly 200 including solid cancers (e.g., breast, prostate, lung, ovarian) leukemias lymphomas. We postulate serum presence sulfonylurea-responsive represents an origin due shedding patient's cancer. If so, antitumor-responsive would represent first reported cell change universally associated all forms human